Fennec Pharmaceuticals (FENC) Shares Outstanding (Diluted Average) (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Shares Outstanding (Diluted Average) of $28.6 million for Q4 2025, up 4.7% year-on-year from $27.3 million in Q4 2024, and up 3.13% on a QoQ basis from $27.7 million in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of Shares Outstanding (Diluted Average) data on file, last reported at $28.6 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 4.7% year-over-year to $28.6 million; the trailing twelve-month figure through Dec 2025 stood at $28.6 million (up 4.7% YoY), and the FY2025 full-year result was $28.6 million, up 4.7% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $28.6 million, up from $27.7 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $31.1 million in Q1 2024 and bottomed at $26.0 million in Q1 2021.
- The 5-year median for Shares Outstanding (Diluted Average) is $26.6 million (2023), against an average of $27.1 million.
- The widest annual swing landed in 2021, when Shares Outstanding (Diluted Average) surged 109611.44%; it then dropped 11.3% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $26.0 million in 2021, then gained by 1.03% to $26.3 million in 2022, then climbed by 1.14% to $26.6 million in 2023, then increased by 2.71% to $27.3 million in 2024, then climbed by 4.7% to $28.6 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $28.6 million (Q4 2025), $27.7 million (Q3 2025), and $27.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 28.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.58 Mn |
| Sep 30, 2025 | 27.71 Mn |
| Jun 30, 2025 | 27.66 Mn |
| Mar 31, 2025 | 27.58 Mn |
| Dec 31, 2024 | 27.29 Mn |
| Sep 30, 2024 | 27.37 Mn |
| Jun 30, 2024 | 27.30 Mn |
| Mar 31, 2024 | 31.09 Mn |
| Dec 31, 2023 | 26.57 Mn |
| Sep 30, 2023 | 26.60 Mn |
| Jun 30, 2023 | 26.47 Mn |
| Mar 31, 2023 | 26.56 Mn |
| Dec 31, 2022 | 26.28 Mn |
| Sep 30, 2022 | 26.11 Mn |
| Jun 30, 2022 | 26.05 Mn |
| Dec 31, 2021 | 26.01 Mn |
| Sep 30, 2021 | 26.01 Mn |
| Mar 31, 2021 | 26.00 Mn |
| Dec 31, 2020 | 23,704.00 |
| Sep 30, 2020 | 22.97 Mn |
| Mar 31, 2020 | 19.90 Mn |
| Mar 31, 2019 | 19.90 Mn |
| Mar 31, 2018 | 18.43 Mn |
| Sep 30, 2017 | 15.74 Mn |
| Jun 30, 2017 | 14.19 Mn |
| Mar 31, 2017 | 13.64 Mn |
| Sep 30, 2016 | 13.64 Mn |
| Jun 30, 2016 | 11.87 Mn |
| Mar 31, 2016 | 10.94 Mn |
| Sep 30, 2015 | 10.79 Mn |
| Jun 30, 2015 | 12.95 Mn |
| Mar 31, 2015 | 11.87 Mn |
| Dec 31, 2014 | 9.87 Mn |
| Sep 30, 2014 | 11.15 Mn |
| Jun 30, 2014 | 9.85 Mn |
| Mar 31, 2014 | 9.77 Mn |
| Dec 31, 2013 | 10.57 Mn |
| Sep 30, 2013 | 8.55 Mn |
| Jun 30, 2013 | 25.64 Mn |
| Mar 31, 2013 | 25.16 Mn |
| Dec 31, 2012 | 25.16 Mn |
| Sep 30, 2012 | 25.16 Mn |
| Jun 30, 2012 | 25,158.00 |
| Mar 31, 2012 | 25,158.00 |
| Dec 31, 2011 | 24,050.00 |
| Sep 30, 2011 | 23.79 Mn |
| Jun 30, 2011 | 25.16 Mn |
| Mar 31, 2011 | 25.00 Mn |
| Dec 31, 2010 | 16.02 Mn |
| Sep 30, 2010 | 20.46 Mn |
| Jun 30, 2010 | 128.23 Mn |